Hydrolases

Vericel To Host Virtual Analyst and Investor Day on October 16, 2020

Retrieved on: 
Friday, October 9, 2020
Hydrolases, Bromelain, Vericel, NASDAQ, Medicine, Health, Finance

CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m.
  • During the event, Vericel executives will provide a general business update as well as current U.S. commercialization plans for NexoBrid (concentrate of proteolytic enzymes enriched in bromelain).
  • For those not available to listen to the live broadcast, a replay will be archived and available at http://investors.vcel.com/events-presentations .
  • Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets.

NREL, UK University Partner To Dive Deeper Into How Enzymes Digest Plastic

Retrieved on: 
Thursday, October 1, 2020
Burkholderiales, Recycling, Hydrolases, Chemical substances, Chemistry, Physical sciences, Ideonella sakaiensis, PETase, Ideonella, MHETase, Polyethylene terephthalate, National Renewable Energy Laboratory

A bacterium,Ideonella sakaiensis201-F6, was discovered in the soil outside of a Japanese PET bottle recycling plant in 2016 and was shown to secrete both PETase and MHETase.

Key Points: 
  • A bacterium,Ideonella sakaiensis201-F6, was discovered in the soil outside of a Japanese PET bottle recycling plant in 2016 and was shown to secrete both PETase and MHETase.
  • The new research combined structural, computational, biochemical, and bioinformatics approaches to reveal molecular insights into its structure and how it functions.
  • Additional research discovered two other bacteria that contain enzymes like MHETase, bringing the total known enzymes that act on this synthetic substrate to three.
  • NREL is the U.S. Department of Energy's primary national laboratory for renewable energy and energy efficiency research and development.

MediWound to Present at Upcoming Investor Conferences in September

Retrieved on: 
Thursday, September 3, 2020
Medicine, Clinical medicine, Branches of biology, Necrosis, Hydrolases, Debridement, Eschar, Bromelain, Biopharmaceutical, Wound

MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.

Key Points: 
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.
  • The product has received marketing authorization from theEuropean Medicines Agencyas well as the Israeli, Argentinian, South Korean, Russian and Peruvian Ministries of Health.
  • MediWounds second innovative product, EscharExis a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.
  • In two Phase 2 studies, EscharEx has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

Retrieved on: 
Tuesday, July 28, 2020
Medicine, Life sciences, Clinical medicine, Necrosis, Hydrolases, Debridement, Eschar, Bromelain, Proteolysis, Biopharmaceutical

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.
  • MediWounds second innovative product, EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.

Global Baking Enzymes Market Analysis 2020-2027 with COVID-19 Impact Estimates and Profiles of 66 Competitors - ResearchAndMarkets.com

Retrieved on: 
Friday, July 17, 2020
Retail, Other Retail, Companies, Economy, Articles, Hydrolases, Lipase, Analytics, General Electric

The "Baking Enzymes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Baking Enzymes - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 306-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • This segment currently accounts for a 12.9% share of the global Baking Enzymes market.
  • In the global Lipase segment, USA, Canada, Japan, China and Europe will drive the 3.8% CAGR estimated for this segment.

Vericel Announces Submission of Biologics License Application to the FDA for NexoBrid for the Treatment of Severe Thermal Burns

Retrieved on: 
Tuesday, June 30, 2020
Medicine, Clinical medicine, Health, Bromelain, Hydrolases, Wound, Debridement, Cosmesis, Thermal burn

Vericel holds an exclusive license for North American commercial rights to NexoBrid.

Key Points: 
  • Vericel holds an exclusive license for North American commercial rights to NexoBrid.
  • A key safety endpoint, non-inferiority in time to complete wound closure compared with patients treated with SOC, was also achieved.
  • Long-term follow-up data to assess cosmesis, function, and quality of life, including 12-month results from the DETECT study, were also included in the submission.
  • The company also holds an exclusive license for North American commercial rights to NexoBrid, a registration-stage biological orphan product for debridement of severe thermal burns.

Insights into the Worldwide Food Enzymes Industry to 2025 - Featuring Royal DSM, Novozymes & Biocatalyst Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, May 25, 2020
Food, Beverage, Retail, Proteins, Branches of biology, Chemistry, Catalysis, Hydrolases, Lipase, Enzyme, Protease, Market

The food enzymes market is bifurcated by type into variants such as carbohydrates, lipases, and proteases.

Key Points: 
  • The food enzymes market is bifurcated by type into variants such as carbohydrates, lipases, and proteases.
  • The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies.
  • These provide the key market participants with the necessary business intelligence and help them understand the future of the food enzyme market.
  • The key areas of focus include the various types of application industry in global food enzyme market, and their specific advantages.

MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020

Retrieved on: 
Wednesday, May 13, 2020
Medicine, Branches of biology, Clinical medicine, Necrosis, Hydrolases, Debridement, Eschar, Bromelain, Proteolysis

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.

Key Points: 
  • To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
  • An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.
  • MediWounds first innovative biopharmaceutical product, NexoBrid, non-surgically and rapidly removes burn eschar without harming viable tissue.
  • MediWounds second innovative product, EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NexoBrid.

Specialty Enzymes Market by Type, Source, Application, Form and Region - Global Forecast to 2025 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020
Pharmaceutical, Science, Health, Other Science, Proteins, Hydrolases, Lipase, Enzymes

The "Specialty Enzymes Market by Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, and Other enzymes), Source, Application (pharmaceuticals, Research & Biotechnology, Diagnostics, and Biocatalysts), Form, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Specialty Enzymes Market by Type (Carbohydrases, Proteases, Lipases, Polymerases & Nucleases, and Other enzymes), Source, Application (pharmaceuticals, Research & Biotechnology, Diagnostics, and Biocatalysts), Form, and Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The specialty enzymes market is projected to grow at a CAGR of 7.1% from 2019 to reach USD 6.6 billion by 2025.
  • However, the growth of the specialty enzymes market is inhibited by factors, such as high adaption costs involved for small & medium-sized enterprises.
  • Furthermore, the technological advancements in the pharmaceutical industry have contributed notably to the growth of the specialty enzymes market in this region.

Enzymes Market Size, Share & Trends Analysis Report By Application, By Product, By Source, By Region And Segment Forecasts, 2020 - 2027

Retrieved on: 
Monday, April 6, 2020
Proteins, Branches of biology, Hydrolases, Chemistry, Enzymes, Catalysis, Posttranslational modification, Protease, Enzyme, Lipase, Carbohydrase

Enzymes Market Size, Share & Trends Analysis Report By Application (Industrial Enzymes, Specialty Enzymes), By Product (Carbohydrase, Proteases, Lipases), By Source, By Region, And Segment Forecasts, 2020 - 2027

Key Points: 
  • Enzymes Market Size, Share & Trends Analysis Report By Application (Industrial Enzymes, Specialty Enzymes), By Product (Carbohydrase, Proteases, Lipases), By Source, By Region, And Segment Forecasts, 2020 - 2027
    The global enzymes market size is expected to reach USD 17.2 billion by 2027, registering a CAGR of 7.1% over the forecast period.
  • Enzymes are also used as feed additives in the animal feed industry.Phytase, protease, and carbohydrase are used extensively in the animal feed industry.
  • Increasing demand for the product in the animal feed industry due to their multi-functional attributes is anticipated to boost the enzymes market growth.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.